Expert review of pharmacoeconomics & outcomes research · 2025
Standardized pharmaceutical service improves medication adherence and reduces anxiety and depression in patients with chronic obstructive pulmonary disease.
СтатьяРандомизированное исследованиеНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Lin Meiying, Chen Youwei, Zou Qifeng, Wang Zhiyong, Chen Zhibin, Liu Yifeng
Аннотация
OBJECTIVE: To evaluate the effects of standardized pharmaceutical service (SPS) on medication adherence, anxiety, and depression in patients with chronic obstructive pulmonary disease (COPD).
RESEARCH DESIGN AND METHODS: A prospective, randomized controlled study design was adopted. 184 COPD patients hospitalized at the First Hospital of Putian City between March and August 2023 were randomly assigned to a control group receiving routine care or observation group receiving SPS provided by clinical pharmacists. SPS included health records establishment, education, medication guidance, psychological support and medication simplification. Patients were followed for 6 months. Eight-Item Morisky Medication Adherence Scale (MMAS-8), the Self-Rating Anxiety Scale (SAS), and the Self-Rating Depression Scale (SDS) were used to assess outcomes.
RESULTS: At 3- and 6-month, the observation group had higher MMAS-8 scores (P < 0.05) and a greater of good-to-moderate adherence at 6 months (66.30% vs.35.87%; P < 0.01). Moderate-to-severe anxiety and depression rates were significantly lower in the observation group (53.26% and 54.35%) than in controls (P < 0.001). Fewer adverse events were recorded in the observation group (3 vs. 8), though not statistically significant.
CONCLUSION: SPS enhance medication adherence and reduce anxiety and depression in COPD patients, supporting its integration into routine COPD management.
RESEARCH DESIGN AND METHODS: A prospective, randomized controlled study design was adopted. 184 COPD patients hospitalized at the First Hospital of Putian City between March and August 2023 were randomly assigned to a control group receiving routine care or observation group receiving SPS provided by clinical pharmacists. SPS included health records establishment, education, medication guidance, psychological support and medication simplification. Patients were followed for 6 months. Eight-Item Morisky Medication Adherence Scale (MMAS-8), the Self-Rating Anxiety Scale (SAS), and the Self-Rating Depression Scale (SDS) were used to assess outcomes.
RESULTS: At 3- and 6-month, the observation group had higher MMAS-8 scores (P < 0.05) and a greater of good-to-moderate adherence at 6 months (66.30% vs.35.87%; P < 0.01). Moderate-to-severe anxiety and depression rates were significantly lower in the observation group (53.26% and 54.35%) than in controls (P < 0.001). Fewer adverse events were recorded in the observation group (3 vs. 8), though not statistically significant.
CONCLUSION: SPS enhance medication adherence and reduce anxiety and depression in COPD patients, supporting its integration into routine COPD management.